AGREEMENT
Exhibit 10.4
This Agreement (“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between:
Tel Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Xxxxxxxx, Xxxxxx, 00000, represented by its authorized representatives (“THM”); and
Xxxx. Xxxx Xxxxxx, ID no. 000000000 of Ramat Gan, Israel (“Xxxx. Xxxxxx”); and
Vascular Biogenics Ltd., Company no. 00-000000-0, a private company duly incorporated under the laws of the State of Israel having its registered office at 6 Xxxx Xxxxxxxxx Street, Or Xxxxxx, Xxxxxx, 00000, represented by its authorized representatives (“VBL” or the “Company”).
WHEREAS: | THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and |
WHEREAS: | THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees; and |
WHEREAS: | Xxxx. Xxxxxx has been an employee of the Hospital and/or the Fund since 1995; and |
WHEREAS: | VBL was established in 1999; and |
WHEREAS: | The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Xxxx. Xxxxxx, and certain other inventors defined herein as Inventors and VBL disagrees, denies and refutes all such claims in their entirety; and |
WHEREAS: | THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder; |
NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties hereby agree and stipulate as follows:
1. | PREAMBLE AND DEFINITIONS |
1.1 | The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof. |
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
1.2 | The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement. |
1.3 | In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter: |
1.3.1 | “Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity. |
1.3.2 | The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA). |
1.3.3 | “Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States, Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service xxxx registrations and applications therefore throughout the world; and (vi) all domain names, uniform resource locators, and other names and locators associated with the internet. |
1.3.4 | The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba. |
2
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
1.3.5 | The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii) any continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon. |
1.3.6 | The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the Company’s IP. |
1.3.7 | “Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes, excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate uses; provided however that the Company doesn’t receive any consideration relating thereto; |
For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph (a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable. |
1.3.8 | “License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly. |
1.3.9 | “License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return for or in connection with the grant of Licences or the grant of an |
3
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments, etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause. |
1.3.10 | “First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such country has been obtained if such approval is required. |
2. | PARTIES’ DECLARATIONS AND UNDERTAKINGS |
2.1 | THM undertakes and covenants as follows: |
2.1.1 | Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right to receive any payment, compensation, funds or securities from Xxxx. Xxxx Xxxxxx and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights, claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s IP now or in the future, (“Released Matters”). |
2.1.2 | Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created, conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property |
4
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or contractors on behalf of the Company to the extent they are not listed in Appendix A. |
2.1.3 | Xxxx Xxxxxx shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties. |
2.2 | Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received. |
3. | LICENSE BY THE COMPANY |
VBL undertakes that any License granted by it shall be subject to the following terms:
5
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
3.1 | The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with such terms. |
3.2 | The License is being granted in a bona fide arms-length commercial transaction. |
3.3 | Non monetary consideration, if any, shall be valued as set forth in this Agreement. |
4. | CONSIDERATION TO THM |
4.1 | VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country: |
4.1.1 | Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”). |
4.1.2 | Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”). |
4.2 | The amounts payable to THM under clause 4.1 shall be paid as follows: |
4.2.1 | Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL receives payment on account of Net Sales. |
4.2.2 | Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL. |
6
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
4.3 | Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”). |
Consideration from Exit Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may pay the Consideration From Exit within 12 months following the closing of the respective Exit Event.
“Exit Event” means any of the following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile or structure of VBL shall not be deemed an Exit Event.
4.4. | Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM, provided that such amounts were not received by THM as Royalties under clause 4.1.1. |
4.5 | All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount applicable to THM in connection with each payment. |
4.6 | The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report the date of execution of such agreement and the date of the First Commercial Sale according to the agreement. |
4.7 | In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be. |
4.8 | The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form reasonably acceptable to THM, signed by the chief financial officer of VBL, |
7
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts payable hereunder; and (c) Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of such Exit will be disclosed orally by the legal counsel of VBL to the head of THM. |
4.9 | The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices. |
4.10 | Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of 4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year. |
4.11 | Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the |
8
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Company conducted for the development of Products; and (ii) sales and marketing efforts. |
5. | INDEMNITY |
5.1 | VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM Claim”). |
5.2 |
5.3 | The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion. |
5.4 | VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product liability and (iii) commercial sales of applicable and relevant Products. |
6. | PATENT RIGHTS |
In the event that the Company decides to abandon its patents in all applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM (“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights.
THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4
9
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
and that any such agreement shall be subject to any limitations and restrictions imposed by applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period.
7. | MISCELLANEOUS |
7.1 | Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel. |
7.2 | Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication including commercial publicity, without the prior written consent of THM. |
7.3 | Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party. Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital. In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement. |
7.4 | Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid, |
10
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
return receipt requested, if sent by Registered Mail and addressed to the address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof. |
7.5 | Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem expedient. |
7.6 | Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties. |
7.7 | Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations, or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings. |
7.8 | THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work as medical doctors for Sheba such as Xxxx. Xxxx Charats, Xxxx. Xxxxxxxxx and Xxxx. Xxxxx Xxxxx, shall belong to Sheba. |
[Remainder of the Page was left intentionally blank]
11
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement.
Tel Hashomer - Medical Research, | Vascular Biogenics Ltd. | |||||||||
Infrastructure and Services Ltd. | ||||||||||
By: | /s/ [Illegible] |
By: | /s/ Xxxx Xxxxxx | |||||||
/s/ Xxxx Xxxxxx Xxxx. Xxxx Xxxxxx |
||||||||||
Approved and Acknowledged | ||||||||||
/s/ [Illegible] The Government of Israel By the Ministry of Health |
12
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Appendix A
INVENTORS
1. Xxxx. Xxxx Xxxxxx
2. Xxxxxxxxx Xxxxxx
3. Xxxxxx Xxxxx
4. Xxxxxxxx Xxxxxx – up to 2003
5. Xxxxx Xxxx
6. Xxxxxxxxxxx Xxxxxxxx
7. Xxx Xxxxxx
8. Xxxxx Xxxxxxx
* | detailed list of inventions is provided under Appendix B. |
13
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Appendix B’ up to 3 Feb 2013
METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS | ||||||||||||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] |
ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS | ||||||||||||||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||||||||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||||||||||||||
52423 |
PCT | 19-Oct-2010 | 12/10/2011 | 3182.041PC01 | Pending |
TREATMENT WITH VB-201 | ||||||||||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||||||||||
[***] |
[***] | [***] | [***] | [***] |
14
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
[***] |
[***] | [***] | [***] | [***] | [***] | |||||||||||
50378 |
PCT | 05-Jan-2010 61/292,226 |
05-Jan-2011 IL2011/000012 |
Publ. Date: 14-Jul-2011 Publ. #: WO2011/083469 |
3182.018PC05 | Expired | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx |
PAF-LIKE HOMOLOGS AND USES THEREOF | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
44504 |
PCT | 16-Oct-2007 60/960,846 |
05-Oct-2008 IL2008/001315 |
Publ. Date: 23-Apr-2009 Publ. #: WO2009/050692 |
Expired | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxx NP |
16-Oct-2007 60/960,846 |
15-Apr-2010 | 05-Oct-2008 205144 |
3182.019IL01 | Aban | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx | |||||||||
00000 |
XXX NP |
16-Oct-2007 60/960,846 |
15-Apr-2010 | 05-Oct-2008 12/738,097 |
3182.0190001 | Aban | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx | |||||||||
48217 |
Europe NP |
16-Oct-2007 60/960,846 |
14-May-2010 | 05-Oct-2008 08808113.8 |
3182.019EP01 | Aban | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx |
15
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent Xx. |
XXXX Xxx | Xxxxxx | Xxxxxxxx | ||||||||
00000 |
PCT | 09-Jul-2004 60/586,219 |
10-Jul-2005 IL2005/000735 |
Publ. Date: 19-Jan-2006 Publ. #: WO2006/006161 |
Expired | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxx NP |
09-Jul-2004 60/586,219 |
09-Jan-2007 | 10-Jul-2005 | 1-Mar-2012 180628 |
3182.020IL00 | GRANTED | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||
00000 |
Xxxxxx DIV |
09-Jul-2004 60/586,219 |
17-Mar-2011 | 10-Jul-2005 211795 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxx DIV |
09-Jul-2004 60/586,219 |
17-Mar-2011 | 10-Jul-2005 211796 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxx NP |
09-Jul-2004 60/586,219 |
09-Feb-2007 | 10-Jul-2005 05758938.4 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 Xxx |
Europe Div |
09-Jul-2004 60/586,219 |
Oct 2012 | 10-Jul-2005 | 3182.020EP10 | Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti |
16
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
33793 Div |
Europe Div |
09-Jul-2004 60/586,219 |
Oct 2012 | 10-Jul-2005 12179533.0 |
3182.020EP20 | Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxx Xxxx XX |
09-Jul-2004 60/586,219 |
31-May-2007 | 10-Jul-2005 07105789.7 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | ||||||||||
00000 |
Xxxxxx NP |
09-Jul-2004 60/586,219 |
09-Jan-2007 | 10-Jul-2005 2,573,396 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxx NP |
09-Jul-2004 60/586,219 |
09-Jan-2007 | 10-Jul-2005 2007-519983 |
24-Jun-2011 4,767,948 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxxx DIV |
09-Jul-2004 60/586,219 |
21-May-2010 | 10-Jul-2005 2010-116964 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxxxx xx Xxxxx NP |
09-Jul-2004 60/586,219 |
09-Feb-2007 | 10-Jul-2005 2007-7003288 |
9-Nov-2012 00-0000000 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxxx NP |
09-Jul-2004 60/586,219 |
28-Feb-2007 | 10-Jul-2005 200580029218.9 |
3-Aug-2011 200580029218.9 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxxx DIV |
09-Jul-2004 60/586,219 |
11-Feb-2010 | 10-Jul-2005 201010128184.1 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
33801 |
Russian Federation NP |
09-Jul-2004 60/586,219 |
09-Feb-2007 | 10-Jul-2005 2007105097 |
20-Sep-2010 2399626 |
Granted | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti |
17
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxxx NP |
09-Jul-2004 60/586,219 |
08-Jan-2007 | 10-Jul-2005 MX/a/ |
17-Mar-2011 284830 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxxxxxxx DIV |
09-Jul-2004 60/586,219 |
09-Jan-2007 | 10-Jul-2005 2007200090 |
2007200090 5 Jan 2012 |
3182.020AU00 | Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||
00000 |
Xxxxxx DIV |
09-Jul-2004 60/586,219 |
14-Jan-2011 | 10-Jul-2005 MX/a/ |
3 Sep 2012 303011 |
Granetd | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxx Xxxxxxx NP |
09-Jul-2004 60/586,219 |
09-Feb-2007 | 10-Jul-2005 553147 |
06-Nov-2010 553147 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxx Xxxxxxx DIV |
09-Jul-2004 60/586,219 |
29-Jun-2010 | 10-Jul-2005 586503 |
10 Oct 2011 586503 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | |||||||||
00000 |
Xxxxx Xxxxxx NP |
09-Jul-2004 60/586,219 |
10-Jul-2005 2007/01178 |
25-Sep-2008 2007/01178 |
Granted | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status | Inventor | ||||||||
02/23345 |
USA CIP |
17-Nov-2000 60/248,582 |
01-May-2002 10/135,447 |
27-Jun-2006 7,067,649 |
Granted | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | ||||||||||
00000 |
XXX DIV |
17-Nov-2000 60/248,582 |
29-Oct-2004 | 01-May-2002 10/975,619 |
25-Aug-2009 7,579,327 |
Granted | HARATS Dror; BREITBART Eyal; XXXXX Xxxx |
18
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
45023 |
USA DIV |
17-Nov-2000 60/248,582 |
03-Jun-2009 | 01-May-2002 12/457,200 |
Pending | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | ||||||||||||
00000 |
XXX DIV |
17-Nov-2000 60/248,582 |
27-Apr-2011 | 01-May-2002 13/094,900 |
Pending | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | ||||||||||||
00000 |
XXX DIV |
17-Nov-2000 60/248,582 |
24-April 2012 | 01-May-2002 13/454,171 |
3182.0350004 | Pending | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | |||||||||||
00000 |
PCT | 01-May-2002 10/135,447 |
30-Apr-2003 IL03/00347 |
Publ. Date: 13- Nov-2003 Publ. #: WO03/093409 |
Expired | HARATS Dror | ||||||||||||
00000 |
Xxxxxxxxx NP |
01-May-2002 10/135,447 |
01-Nov-2004 | 30-Apr-2003 200406381-4 |
30-May-2008 107841 [WO 03/093409] |
Granted | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | |||||||||||
00000 |
South Africa NP |
01-May-2002 10/135,447 |
05-Nov-2004 | 30-Apr-2003 2004/8989 |
26-Jul-2006 2004/8989 |
Granted | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | |||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
00000 |
Xxxxx NP |
01-May-2002 10/135,447 |
01-Nov-2004 | 30-Apr-2003 2004-501545 |
Abandoned | HARATS Dror | ||||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | [***] |
19
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxx NP |
01-May-2002 10/135,447 |
01-Nov-2004 | 30-Apr-2003 2,483,996 |
Abandoned | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | ||||||||||
00000 |
Mexico NP |
01-May-2002 10/135,447 |
28-Oct-2004 | 30-Apr-2003 PA/a/2004/010711 |
Abandoned | HARATS Dror; BREITBART Eyal; XXXXX Xxxx | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] |
COMBINED TREATMENT UTILIZING VB-201 | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
50379 |
PCT | 05-Jan-2010 61/292,226 |
05-Jan-2011 IL2011/000010 |
Publ. Date: 14-Jul-2011 Publ. #: WO2011/083467 |
Expired | XXXXX Xxxx; BREITBART Eyal; XXXXX Xxxx | ||||||||||
US NP | 05-Jan-2010 61/292,226 |
5-July 2012 | 05-Jan-2011 13/520,713 |
3182.0160005 | Pending | XXXXX Xxxx; BREITBART Eyal; XXXXX Xxxx | ||||||||||
EP NP | 05-Jan-2010 61/292,226 |
1-Aug 2012 | 3182.016EP05 | Pending | XXXXX Xxxx; BREITBART Eyal; XXXXX Xxxx |
20
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
JP NP | 05-Jan-2010 61/292,226 |
4-July 2012 | 3182.016JP05 | Pending | XXXXX Xxxx; BREITBART Eyal; XXXXX Xxxx |
POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
41795 |
PCT | 31-Jul-2006 60/834,157 |
31-Jul-2007 IL2007/000959 |
Publ. Date: 07-Feb-2008 Publ. #: WO/2008/015675 |
Expired | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxx NP |
31-Jul-2006 60/834,157 |
26-Mar-2009 | 31-Jul-2007 200780035863.0 |
8-Aug 2012 ZL20078003 5863.0 |
3182.040CN01 | Granted | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||
00000 |
Xxxxx Div |
31-Jul-2006 60/834,157 |
26-June-2012 | 31-Jul-2007 201210210646.3 |
3182.040CN11 | Pending | XXX Xxxxxx; BREITBART Eyal; BANGIO Xxxxxx | |||||||||
00000 |
XXX NP |
31-Jul-2006 60/834,157 |
02-Feb-2009 | 31-Jul-2007 12/309,856 |
Abandoned | XXX Xxxxxx; BREITBART Eyal; BANGIO Xxxxxx | ||||||||||
00000 |
XXX DIV |
31-Jul-2006 60/834,157 |
20-Jun-2011 | 31-Jul-2007 13/163,776 |
Pending | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxx NP |
31-Jul-2006 60/834,157 |
29-Jan-2009 | 31-Jul-2007 196792 |
Pending | XXX Xxxxxx; BREITBART Eyal; BANGIO Livnat |
21
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxxxxx NP |
31-Jul-2006 60/834,157 |
02-Feb-2009 | 31-Jul-2007 2007280017 |
26-July 2012 2007280017 |
3182.040AU01 | Granted | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||
00000 |
Xxxxxxxxx Div |
31-Jul-2006 60/834,157 |
12-July 2012 | 31-Jul-2007 2012204128 |
3182.040AU11 | Pending | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | |||||||||
00000 |
Xxxxx NP |
31-Jul-2006 60/834,157 |
02-Feb-2009 | 31-Jul-2007 2009-522416 |
Pending | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxxxx of Korea NP |
31-Jul-2006 60/834,157 |
27-Feb-2009 | 31-Jul-2007 2009-7004288 |
Abandoned | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxx NP |
31-Jul-2006 60/834,157 |
29-Jan-2009 | 31-Jul-2007 MX/a/ |
Pending | XXX Xxxxxx; BREITBART Eyal; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxx Xxxxxxx NP |
31-Jul-2006 60/834,157 |
26-Jan-2009 | 31-Jul-2007 574410 |
9 July 2012 574410 |
3182.040NZ01 | Granted | XXX Xxxxxx; BREITBART Eyal; BANGIO Livnat |
22
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxx Xxxxxx NP |
31-Jul-2006 60/834,157 |
26-Jan-2009 | 31-Jul-2007 2009/00581 |
31-Mar-2010 2009/00581 |
Granted | XXX Xxxxxx; BREITBART Eyal; BANGIO Livnat | |||||||||
00000 |
Xxxxxxxxx NP |
31-Jul-2006 60/834,157 |
30-Jan-2009 | 31-Jul-2007 200900642-0 |
30-Jun-2011 149616[WO2008/015675] |
Granted | XXX Xxxxxx; BREITBART Eyal; BANGIO Livnat |
TREATMENT WITH VB-201 | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | |||||||||||
50377 |
PCT | 05-Jan-2010 61/292,226 |
05-Jan-2011 IL2011/000008 |
Publ. Date: 14-Jul-2011 Publ. #: WO2011/083465 |
Expired | XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx; XXXX Xxxxxx; XXXXX Xxxx | ||||||||||
US NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.0170005 | Pending | |||||||||||
AU NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017AU05 | Pending | |||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
CANADA NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017CA05 | Pending |
23
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
China NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017CN05 | Pending | |||||||||||
HK NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017HK05 | Pending | |||||||||||
EP NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017EP05 | Pending | |||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
Japan NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017JP05 | Pending | |||||||||||
South Korea NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017KR05 | Pending | |||||||||||
MX NP | 05-Jan-2010 61/292,226 |
June 2012 | 05-Jan-2011 | 3182.017MX05 | Pending | |||||||||||
[***] | [***] | [***] | [***] | [***] | [***] |
24
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent Xx. |
XXXX Xxx | Xxxxxx | Xxxxxxxx | ||||||||
00000 |
PCT | 12-Jan-2010 61/294,158 |
12-Jan-2011 IB2011/050137 |
Publ. Date: 21-Jul-2011 Publ. #: WO2011/086509 |
Expired | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx | ||||||||||
US NP | 12-Jan-2010 61/294,158 |
June 2012 | 12-Jan-2011 | 3182.0330001 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx | ||||||||||
EP NP | 12-Jan-2010 61/294,158 |
June 2012 | 12-Jan-2011 | 3182.033EP01 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx | ||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
JP NP | 12-Jan-2010 61/294,158 |
June 2012 | 12-Jan-2011 | 3182.033JP01 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx | ||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | [***] |
25
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
01/22753 |
PCT | 24-Nov-2000 60/252,574 |
22-Nov-2001 IL01/01080 |
Publ. Date: 30-May-2002 Publ. #: WO02/41827 |
Expired | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | ||||||||||
26035 |
Europe NP |
22-Nov-2000 60/252,574 |
15-May-2003 | 22-Nov-2001 01997274.4 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | ||||||||||
52529 |
EP Div | 22-Nov-2000 60/252,574 |
17-Nov 2011 | 22-Nov-2001 11189562.9 |
3182.021EP11 | Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
27265 |
Hong Kong NP |
24-Nov-2000 60/252,574 |
12-Dec-2003 | 22-Nov-2001 03109096.1 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxx NP |
22-Nov-2000 60/252,574 |
20-May-2003 | 22-Nov-2001 156015 |
10-May-2008 156015 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxxx DIV |
24-Nov-2000 60/252,574 |
20-Jul-2006 | 22-Nov-2001 176976 |
1-Dec 2012 176976 |
3182.021IL11 | Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx |
26
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxx NP |
22-Nov-2000 60/252,574 |
22-May-2003 | 22-Nov-2001 796/CHENP/2003 |
19-Sep-2008 223638 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxxx NP |
22-Nov-2000 60/252,574 |
22-May-2003 | 22-Nov-2001 2,429,817 |
3182.021CA01 | Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
26040 |
Australia NP |
22-Nov-2000 60/252,574 |
23-May-2003 | 22-Nov-2001 0000000000 |
21-Dec-2006 0000000000 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxx NP |
22-Nov-2000 60/252,574 |
23-May-2003 | 22-Nov-2001 2002-544008 |
01-Aug-2008 4,162,486 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxx DIV |
24-Nov-2000 60/252,574 |
10-Jun-2008 | 22-Nov-2001 2008-151301 |
25 May 2012 5001906 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxx NP |
22-Nov-2000 60/252,574 |
22-Jul-2003 | 22-Nov-2001 01822215.3 |
06-Jan-2010 ZL01822215.3 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
26043 |
Republic of Korea NP |
22-Nov-2000 60/252,574 |
24-May-2003 | 22-Nov-2001 2003-7006991 |
17-Oct-2008 865142 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxxx NP |
22-Nov-2000 60/252,574 |
22-May-2003 | 22-Nov-2001 PA/a/2003/004517 |
02-Sep-2009 269738 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
00000 |
Xxxxxx DIV |
24-Nov-2000 60/252,574 |
12-Jun-2009 | 22-Nov-2001 MX/a/2009/006365 |
2 December 2011 293020 |
3182.021MX11 | Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS |
27
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Xxxxxxxx | ||||||||
00000 |
XXX CIP |
17-Nov-2000 60/248,582 |
30-Apr-2007 11/790,992 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | |||||||||||
43177 |
PCT | 30-Apr-2007 11/790,992 |
27-Apr-2008 IL2008/000543 |
Publ. Date: 06-Nov-2008 Publ. #: WO2008/132729 |
Expired | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
47030 |
Europe NP |
30-Apr-2007 11/790,992 |
27-Nov-2009 | 27-Apr-2008 08738245.3 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
48882 |
Hong Kong NP |
30-Apr-2007 11/790,992 |
11-Jun-2010 | 27-Apr-2008 10105838.3 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
00000 |
Xxxxx NP |
30-Apr-2007 11/790,992 |
30-Oct-2009 | 27-Apr-2008 2010-505002 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
00000 |
Xxxxxx NP |
30-Apr-2007 11/790,992 |
27-Oct-2009 | 27-Apr-2008 2,685,394 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
00000 |
Xxxxx NP |
30-Apr-2007 11/790,992 |
30-Dec-2009 | 27-Apr-2008 200880022935.2 |
3182.039CN01 | Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx |
28
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxxxxxx NP |
30-Apr-2007 11/790,992 |
27-Nov-2009 | 27-Apr-2008 2008243817 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
47035 |
Republic of Korea NP |
30-Apr-2007 11/790,992 |
18-Nov-2009 | 27-Apr-2008 2009-7024041 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxx NP |
30-Apr-2007 11/790,992 |
26-Oct-2009 | 27-Apr-2008 201760 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
00000 |
Xxxxxx NP |
30-Apr-2007 11/790,992 |
29-Oct-2009 | 27-Apr-2008 MX/a/2009/011750 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
47039 |
New Zealand NP |
30-Apr-2007 11/790,992 |
27-Nov-2009 | 27-Apr-2008 581511 |
5 June 2012 581511 |
3182.039NZ01 | Granetd | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||
47040 |
South Africa NP |
30-Apr-2007 11/790,992 |
25-Nov-2009 | 27-Apr-2008 2009/08331 |
29-Dec-2010 2009/08331 |
Granted | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | |||||||||
00000 |
Xxxxxxxxx NP |
30-Apr-2007 11/790,992 |
30-Oct-2009 | 27-Apr-2008 200907209-1 |
15 May 2012 156740 |
3182.039SG01 | Granted | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx |
29
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR DEFICIENT MICE | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
01/23033 |
PCT | 04-Jan-2001 60/259,512 |
03-Jan-2002 IL02/00005 |
Publ. Date: 11-Jul-2002 Publ. #: WO02/053092 |
Expired | HARATS Dror; XXXXXX Xxxxx | ||||||||||
00000 |
Xxxxxx NP |
04-Jan-2001 60/259,512 |
03-Jul-2003 | 03-Jan-2002 156770 |
Allowed | HARATS Dror; XXXXXX Xxxxx | ||||||||||
00000 |
Xxxxx NP |
04-Jan-2001 60/259,512 |
04-Jul-2003 | 03-Jan-2002 1044/CHENP/ |
19-Sep-2008 223640 |
Granted | HARATS Dror; XXXXXX Xxxxx | |||||||||
00000 |
XXX NP |
04-Jan-2001 60/259,512 |
02-Jul-2003 | 03-Jan-2002 10/451,370 |
09-Oct-2007 7,279,459 |
Granted | HARATS Dror; XXXXXX Xxxxx | |||||||||
26050 |
Australia NP |
04-Jan-2001 60/259,512 |
11-Jul-2003 | 03-Jan-2002 2002225301 |
03-Mar-2006 2002225301 |
Granted | HARATS Dror; XXXXXX Xxxxx |
30
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxx NP |
04-Jan-2001 60/259,512 |
03-Jul-2003 | 03-Jan-2002 2002-554043 |
26-Sep-2008 4,191,997 |
Granted | HARATS Dror; XXXXXX Xxxxx | |||||||||
00000 |
Xxxxx NP |
04-Jan-2001 60/259,512 |
04-Sep-2003 | 03-Jan-2002 02805950.6 |
Pending | HARATS Dror; XXXXXX Xxxxx | ||||||||||
00000 |
Xxxxxx NP |
04-Jan-2001 60/259,512 |
01-Jun-2003 | 03-Jan-2002 PA/a/2003/006043 |
17-Mar-2009 265173 |
Granted | HARATS Dror; XXXXXX Xxxxx | |||||||||
26045 |
Europe NP |
04-Jan-2001 60/259,512 |
18-Jul-2003 | 03-Jan-2002 02715682.7 |
Abandoned | HARATS Dror; XXXXXX Xxxxx | ||||||||||
27463 |
Hong Kong NP |
04-Jan-2001 60/259,512 |
28-Jan-2004 | 03-Jan-2002 04100565.1 |
Abandoned | HARATS Dror; XXXXXX Xxxxx | ||||||||||
00000 |
Xxxxxx NP |
04-Jan-2001 60/259,512 |
03-Jul-2003 | 03-Jan-2002 2,433,781 |
Abandoned | HARATS Dror; XXXXXX Xxxxx | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] |
31
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
PCT | Sept. 1, 2011 61/529,989 |
Aug. 31, 2012 PCT/US2012/053533 |
3182.013PC01 | Pending | XXXX Xxxxxx; XXXXX Xxxxxx M.; XxXXXXXXXX Xxxx; XXXXXXX Xxx; XXXXXXXXX Xxxxxxx | |||||||||||
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
|
Status | Xxxxxxxx | ||||||||
00000 |
XXX CIP |
17-Nov-2000 60/248,582 |
23-Feb-2006 11/359,513 |
18 October 2011 8,039,261 |
3182.0380000 | Granted | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | |||||||||
37180 |
PCT | 23-Feb-2006 11/359,513 |
22-Feb-2007 IL2007/000242 |
Publ. Date: 30-Aug-2007 Publ. #: WO2007/096882 |
Expired | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; BANGIO Xxxxxx | ||||||||||
00000 |
XXX NP |
17-Nov-2000 60/248,582 |
20-Aug-2008 | 22-Feb-2007 12/224,178 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; BANGIO Livnat; XXXXX Xxxxxxx | ||||||||||
44708 |
Europe NP |
23-Feb-2006 11/359,513 |
28-Aug-2008 | 22-Feb-2007 07713267.8 |
Pending | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; BANGIO Livnat |
32
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxx NP |
23-Feb-2006 11/359,513 |
19-Aug-2008 | 22-Feb-2007 193554 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; BANGIO Livnat | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxx NP |
23-Feb-2006 11/359,513 |
20-Aug-2008 | 22-Feb-2007 2,638,829 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxxxxx NP |
23-Feb-2006 11/359,513 |
23-Sep-2008 | 22-Feb-2007 2007219088 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxx NP |
23-Feb-2006 11/359,513 |
25-Aug-2008 | 22-Feb-2007 2008-555946 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxx NP |
23-Feb-2006 11/359,513 |
21-Oct-2008 | 22-Feb-2007 200780014285.2 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxxxx of Korea NP |
23-Feb-2006 11/359,513 |
22-Sep-2008 | 22-Feb-2007 2008-7023144 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
Xxxxxx NP |
23-Feb-2006 11/359,513 |
22-Aug-2008 | 22-Feb-2007 MX/a/2008/010859 |
Abandoned | HARATS Dror; XXXXXXXXXXX Xxxxxxxx; BREITBART Eyal; XXXXX Xxxxxxx; BANGIO Livnat | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] |
33
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status | Xxxxxxxx | ||||||||
00000 |
XXX CIP |
09-Jul-2004 60/586,219 |
09-Jan-2007 11/650,973 |
05-Oct-2010 7,807,847 |
3182.0200001 | Granted | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | |||||||||
49396 |
USA DIV |
09-Jul-2004 60/586,219 |
24-Aug-2010 | 09-Jan-2007 12/861,921 |
28- Feb 2012 8,124,800 |
3182.0200002 | Granted | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | ||||||||
52800 |
USA DIV | 09-Jul-2004 60/586,219 |
May 24, 2012 | January 26, 2012 13/358,573 |
3182.0200003 | Pending | XXXXXXXX Xxxxxx; KOVALEVSKI | |||||||||
USA CIP | 09-Jul-2004 60/586,219 |
Nov. 9, 2012 13/672,811 |
3182.0200004 | Pending | XXXXXXXX Xxxxxx; KOVALEVSKI | |||||||||||
US CON | 09-Jul-2004 60/586,219 |
Dec. 10, 2012 13/709,198 |
3182.0200005 | Pending | XXXXXXXX Xxxxxx; KOVALEVSKI |
IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS |
34
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent Xx. |
XXXX Xxx |
Xxxxxx |
Xxxxxxxx | ||||||||
00000 |
PCT | 09-Jan-2007 11/650,973 |
02-Jan-2008 IL2008/000013 |
Publ. Date: 17-Jul-2008 Publ. #: WO2008/084472 |
Expired | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxx Xxxxxx NP |
09-Jan-2007 11/650,973 |
02-Jan-2008 2009/05601 |
26-May-2010 2009/05601 |
Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxx Xxxxxxx NP |
09-Jan-2007 11/650,973 |
07-Aug-2009 | 02-Jan-2008 578947 |
4-Dec 2011 578947 |
3182.020NZ01 | Granted | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||
00000 |
Xxx Xxxxxxx DIV |
09-Jan-2007 11/650,973 |
15-Jun-2011 | 02-Jan-2008 593529 |
3182.020NZ11 | Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | |||||||||
[***] | [***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
00000 |
Xxxxxxxxx NP |
09-Jan-2007 11/650,973 |
07-Aug-2009 | 02-Jan-2008 2008204238 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxx NP |
09-Jan-2007 11/650,973 |
09-Jul-2009 | 02-Jan-2008 MX/a/2009/007422 |
9-Jan 2012 294470 |
Granted | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | |||||||||
[***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
00000 |
Xxxxxx NP |
09-Jan-2007 11/650,973 |
09-Jul-2009 | 02-Jan-2008 199792 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxx NP |
09-Jan-2007 11/650,973 |
31-Aug-2009 | 02-Jan-2008 200880006707.6 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti |
35
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxxxxx of Korea NP |
09-Jan-2007 11/650,973 |
27-Jul-2009 | 02-Jan-2008 2009-7015780 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxx NP |
09-Jan-2007 11/650,973 |
09-Jul-2009 | 02-Jan-2008 2009-545295 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | ||||||||||
00000 |
Xxxxxx NP |
09-Jan-2007 11/650,973 |
06-Jul-2009 | 02-Jan-2008 2,674,902 |
Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxxxx NP |
09-Jan-2007 11/650,973 |
07-Aug-2009 | 02-Jan-2008 08700247.3 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | ||||||||||
Europe Div |
09-Jan-2007 11/650,973 |
July 27, 2012 | 02-Jan-2008 EP 12178298.1 |
3182.020EP11 | Pending | XXXXXXXX Xxxxxx; XXXXXXXXXX-XXXXX Xxx | ||||||||||
00000 |
Xxxx Xxxx XX |
16-Mar-2010 | 02-Jan-2008 10102729.2 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti | |||||||||||
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT |
36
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | |||||||||||
50375 |
PCT | 05-Jan-2010 61/282,228 |
05-Jan-2011 IL2011/000007 |
Publ. Date: 14-Jul-2011 Publ. #: WO2011/083464 |
Expired | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
US NP | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.0310002 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
EP | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031EP02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
IL | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031IL02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
JP | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031JP02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | |||||||||||
MX | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031MX02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx |
37
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
[***] | [***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
Canada |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031CA02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
Au |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.031AU02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXX Xxxxxx; XXXXX Xxxx; XXXXX Xxxx | ||||||||||
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | |||||||||||
50376 |
PCT | 05-Jan-2010 61/282,228 |
05-Jan-2011 IL2011/000009 |
Publ. Date: 14-Jul-2011 Publ. #: WO2011/083466 |
3182.032PC02 | Expired | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. |
38
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
US NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.0320002 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
EU NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032EP02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
IL NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032IL02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
[***] | ||||||||||
JP NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032JP02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
KR NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032KR02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
MX NP |
05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032MX02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
39
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
CA NP | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032CA02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
AU NP | 05-Jan-2010 61/282,228 |
June 2012 | 05-Jan-2011 | 3182.032AU02 | Pending | BREITBART Eyal; BANGIO Livnat; XXXXX Xxxx; XXXXXXX Xxxxxx J. | ||||||||||
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry |
Filing Date Application No. |
Issue Date Patent No. |
Status |
Xxxxxxxx | |||||||||
00000 |
XXX CIP |
27-May-2003 10/445,347 |
28-Sep-2006 11/528,657 |
01-Dec-2009 7,625,882 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx; XXXXXX Xxxxxx | ||||||||||
00000 |
XXX DIV |
27-May-2003 10/445,347 |
14-Oct-2009 | 28-Sep-2006 12/588,371 |
05-Jul-2011 7,973,023 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx; XXXXXX Xxxxxx | |||||||||
00000 |
XXX CON |
27-May-2003 10/445,347 |
13-Apr-2011 | 28-Sep-2006 13/085,542 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx; XXXXXX Xxxxxx |
AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF ATHEROSCLEROSIS |
40
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
00/21414 |
Israel Basic |
04-Oct-1998 126447 |
30-Dec-2004 126447 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||||
A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Inventor | ||||||||
01/21558 |
PCT | 04-Oct-1998 126447 |
01-Apr-2001 | 30-Sep-1999 IL99/00519 |
Publ. Date: 13-Apr-2000 Publ. #: WO00/20019 |
Expired | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||
01/21884 |
Europe NP |
04-Oct-1998 126447 |
30-Sep-1999 99970026.3 |
14-May-2003 1126867 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
01/21886 |
Canada NP |
04-Oct-1998 126447 |
30-Sep-1999 2,345,445 |
24-Aug-2010 2,345,445 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
01/21887 |
Australia NP |
04-Oct-1998 126447 |
30-Sep-1999 59966/99 |
28-Aug-2003 760582 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
01/21888 |
China NP |
04-Oct-1998 126447 |
04-Apr-2001 | 30-Sep-1999 99814030.9 |
24-Nov-2004 ZL99814030.9 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||
02/23904 |
Hong Kong NP |
04-Oct-1998 126447 |
19-Jul-2002 | 30-Sep-1999 02105365.4 |
18-Nov-2005 HK1043743 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||
00000 |
Xxxxx DIV |
04-Oct-1998 126447 |
23-Sep-2004 | 30-Sep-1999 200410011940.7 |
05-Nov-2008 ZL200410011940.7 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||
30562 |
Hong Kong DIV |
04-Oct-1998 126447 |
28-Sep-2005 | 30-Sep-1999 05108561.7 |
21-Aug-2009 HK1076600 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx |
41
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
01/21889 |
Singapore NP |
04-Oct-1998 126447 |
30-Sep-1999 200101998-3 |
30-Apr-2003 80182 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
00/00000 |
Xxxxx NP |
04-Oct-1998 126447 |
30-Sep-1999 2000-573378 |
Pending | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | |||||||||||
01/21891 |
Hungary NP |
04-Oct-1998 126447 |
30-Sep-1999 | 30-Sep-1999 P0104410 |
Pending | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | |||||||||||
01/21893 |
Republic of Korea NP |
04-Oct-1998 126447 |
30-Sep-1999 2001-7004285 |
02-Feb-2007 680707 |
Granted | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
01/21885 |
USA NP |
04-Oct-1998 126447 |
30-Mar-2001 | 30-Sep-1999 09/806,400 |
Abandoned | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
01/22498 |
USA CON |
04-Oct-1998 126447 |
04-Sep-2001 | 30-Sep-1999 09/944,592 |
Abandoned | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx | ||||||||||
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE | ||||||||||||||||
Our Ref |
Country | Earliest Priority | Entry Date | Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref | Status | Xxxxxxxx | ||||||||
00000 |
XXX CIP |
04-Oct-1998 126447 |
15-Apr-2005 11/106,665 |
Abandoned | HARATS Dror; XXXXXXXXX Xxxxxx; XXXXXX Xxxxx; XXXXX Xxxx |
42
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Xxxxxxxx | ||||||||
00000 |
XXX CIP |
22-Nov-2000 60/252,574 |
27-May-2003 10/445,347 |
04-Jan-2005 6,838,452 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
00000 |
XXX DIV |
24-Nov-2000 60/252,574 |
24-Nov-2003 | 27-May-2003 10/718,596 |
06-Mar-2007 7,186,704 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
XXX DIV |
24-Nov-2000 60/252,574 |
19-Jul-2005 | 27-May-2003 11/183,884 |
17-Mar-2009 7,504,388 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
XXX DIV |
24-Nov-2000 60/252,574 |
17-Feb-2009 | 27-May-2003 12/371,930 |
22-Feb-2011 7,893,291 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
XXX CON |
24-Nov-2000 60/252,574 |
06-Jan-2011 | 27-May-2003 12/985,365 |
17 April 2012 8,158,611 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
53355 |
USA CON |
24-Nov-2000 60/252,574 |
March 27, 2012 | 27-May-2003 13/431,262 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS |
43
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent Xx. |
XXXX Xxx |
Xxxxxx |
Xxxxxxxx | ||||||||
00000 |
PCT | 27-May-2003 10/445,347 |
27-May-2004 IL2004/000453 |
Publ. Date: 09-Dec-2004 Publ. #: WO2004/106486 |
Expired | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | ||||||||||
00000 |
XXX NP |
27-May-2003 10/445,347 |
25-Apr-2008 | 27-May-2004 10/567,543 |
08-Mar-2011 7,902,176 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
Xxxxxx NP |
27-May-2003 10/445,347 |
25-Nov-2005 | 27-May-2004 pa/A/2005/012784 |
14-Oct-2008 261341 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx | |||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
30947 |
Europe NP |
27-May-2003 10/445,347 |
07-Dec-2005 | 27-May-2004 04735088.9 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
32340 |
Hong Kong NP |
27-May-2003 10/445,347 |
03-Aug-2006 | 27-May-2004 06108608.1 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
00000 |
Xxxxx NP |
27-May-2003 10/445,347 |
30-Nov-2005 | 27-May-2004 2006-531006 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
[***] | [***] | [***] | [***] | [***] | [***] | [***] |
44
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxxx NP |
27-May-2003 10/445,347 |
28-Nov-2005 | 27-May-2004 2,527,483 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
00000 |
Xxxxx NP |
27-May-2003 10/445,347 |
01-Nov-2005 | 27-May-2004 200480021217.5 |
22-Dec-2010 ZL200480021217.5 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
Xxxxx DIV |
27-May-2003 10/445,347 |
25-Oct-2010 | 27-May-2004 201010537971.1 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | ||||||||||
30951 |
Australia NP |
27-May-2003 10/445,347 |
13-Dec-2005 | 27-May-2004 2004243695 |
17-Mar-2011 2004243695 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
30952 |
Republic of Korea NP |
27-May-2003 10/445,347 |
28-Nov-2005 | 27-May-2004 2005-7022741 |
3-Nov 2011 1081977 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
50809 |
Republic of Korea DIV |
27-May-2003 10/445,347 |
18-Feb-2011 | 27-May-2004 2011-7003840 |
23 Feb 2012 00-0000000 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
30953 |
New Zealand NP |
27-May-2003 10/445,347 |
01-Dec-2005 | 27-May-2004 544285 |
12-Mar-2009 544285 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx |
45
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
00000 |
Xxxxx Xxxxxx NP |
27-May-2003 10/445,347 |
01-Dec-2005 | 27-May-2004 2005/09929 |
27-Dec-2006 2005/9929 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
00000 |
Xxxxx NP |
27-May-2003 10/445,347 |
27-Dec-2005 | 27-May-2004 3555/CHENP/2005 |
26-Mar-2009 232654 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
30957 |
Russian Federation NP |
27-May-2003 10/445,347 |
01-Dec-2005 | 27-May-2004 2005140666 |
27-Jul-2009 2362567 |
Granted | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx | |||||||||
46052 |
Russian Federation DIV |
27-May-2003 10/445,347 |
06-Apr-2009 | 27-May-2004 2009112686 |
Pending | HARATS Dror; XXXXXX Xxxxx; XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx |
OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] | [***] | [***] | [***] | [***] |
46
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
46530 |
PCT | 08-Oct-2008 61/103,571 |
01-Oct-2009 IL2009/000949 |
Publ. Date: 15-Apr-2010 Publ. #: WO2010/041242 |
Expired | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx | ||||||||||
50053 |
USA NP |
08-Oct-2008 61/103,571 |
06-Apr-2011 | 01-Oct-2009 13/122,766 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx | ||||||||||
50054 |
Europe NP |
08-Oct-2008 61/103,571 |
20-Apr-2011 | 01-Oct-2009 09818874.1 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx | ||||||||||
00000 |
Xxxxxx NP |
08-Oct-2008 61/103,571 |
05-Apr-2011 | 01-Oct-2009 212153 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] |
47
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
31865 |
PCT | 15-Apr-2005 60/671,500 |
11-Apr-2006 IL2006/000467 |
Publ. Date: 19-Oct-2006 Publ. #: WO2006/109312 |
Expired | XXXXX Xxxx; BREITBART Eyal | ||||||||||
41853 |
Europe NP |
15-Apr-2005 60/671,500 |
24-Oct-2007 | 11-Apr-2006 06728268.1 |
Abandoned | XXXXX Xxxx; BREITBART Eyal | ||||||||||
41854 |
USA NP |
15-Apr-2005 60/671,500 |
10-Oct-2007 | 11-Apr-2006 11/918,141 |
Abandoned | XXXXX Xxxx; BREITBART Eyal | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] |
NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
OXIDIZED LIPID COMPOUNDS AND USES THEREOF |
48
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent Xx. |
XXXX Xxx |
Xxxxxx |
Xxxxxxxx | ||||||||
00000 |
PCT | 06-Nov-2008 61/193,220 |
05-Nov-2009 IL2009/001049 |
Publ. Date: 14-May-2010 Publ. #: WO2010/052718 |
Expired | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx | ||||||||||
50603 |
USA NP |
06-Nov-2008 61/193,220 |
05-May-2011 | 05-Nov-2009 13/127,717 |
Pending | XXXXXXXX Xxxxxx; KOVALEVSKI-ISHAI Eti; XXXXX Xxxx; BREITBART Eyal; XXXXXX Xxxxxx; XXXXXX Xxxx; FEIGE Erez | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
50605 |
Europe NP |
06-Nov-2008 61/193,220 |
16-May-2011 | 05-Nov-2009 09824498.1 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
51983 |
Hong Kong NP |
05-Nov-2009 | Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||||
50606 |
Canada NP |
06-Nov-2008 61/193,220 |
13-Apr-2011 | 05-Nov-2009 2,740,726 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] |
49
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
50608 |
Australia NP |
06-Nov-2008 61/193,220 |
15-Apr-2011 | 05-Nov-2009 2009312355 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
50609 |
New Zealand NP |
06-Nov-2008 61/193,220 |
19-Apr-2011 | 05-Nov-2009 592357 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
50611 |
Japan NP |
06-Nov-2008 61/193,220 |
06-May-2011 | 05-Nov-2009 | Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
50612 |
Republic of Korea NP |
06-Nov-2008 61/193,220 |
02-Jun-2011 | 05-Nov-2009 2011-7012700 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
50613 |
Mexico NP |
06-Nov-2008 61/193,220 |
04-May-2011 | 05-Nov-2009 MX/a/2011/004773 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
50
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
50614 |
Russian Federation NP |
06-Nov-2008 61/193,220 |
06-Jun-2011 | 05-Nov-2009 2011122729 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez | ||||||||||
50615 |
China NP |
06-Nov-2008 61/193,220 |
30-Jun-2011 | 05-Nov-2009 200980153378.2 |
Pending | HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez |
ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC PROMOTER | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
02/23346 |
PCT | 19-Oct-2001 60/330,118 |
01-May-2002 IL02/00339 |
Publ. Date: 24-Apr-2003 Publ. #: WO03/033514 |
Expired | HARATS Dror; GREENBERGER Shoshana | ||||||||||
27526 |
USA NP |
19-Oct-2001 60/330,118 |
12-Apr-2004 | 01-May-2002 10/490,746 |
08-Sep-2009 7,585,666 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal |
51
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
44506 |
USA DIV |
19-Oct-2001 60/330,118 |
08-Aug-2008 | 01-May-2002 12/222,439 |
02-Aug-2011 7,989,427 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
51506 |
USA DIV |
19-Oct-2001 60/330,118 |
20-Jun-2011 | 01-May-2002 13/163,767 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
27527 |
Europe NP |
19-Oct-2001 60/330,118 |
21-Apr-2004 | 01-May-2002 02801473.6 |
22-Sep-2010 1436313 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
29028 |
Hong Kong NP |
19-Oct-2001 60/330,118 |
06-Jan-2005 | 01-May-2002 05100081.5 |
01-Apr-2011 HK1067641 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
49785 |
Europe DIV |
19-Oct-2001 60/330,118 |
17-Sep-2010 | 01-May-2002 EP10177257.2 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
47553 |
Europe DIV |
19-Oct-2001 60/330,118 |
18-Nov-2009 | 01-May-2002 09176343.3 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
49931 |
Hong Kong DIV |
19-Oct-2001 60/330,118 |
10-Dec-2010 | 01-May-2002 10111522.2 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
51004 |
Hong Kong DIV |
19-Oct-2001 60/330,118 |
27-Apr-2011 | 01-May-2002 11104228.3 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
27528 |
Japan NP |
19-Oct-2001 60/330,118 |
16-Apr-2004 | 01-May-2002 2003-536253 |
22-Aug-2008 4,173,446 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
27529 |
Republic of Korea NP |
19-Oct-2001 60/330,118 |
17-Apr-2004 | 01-May-2002 2004-7005720 |
24-Oct-2008 866117 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal |
52
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
27530 |
India NP |
19-Oct-2001 60/330,118 |
19-Apr-2004 | 01-May-2002 801/CHENP/2004 |
26-Dec-2008 226357 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
27531 |
China NP |
19-Oct-2001 60/330,118 |
09-Jun-2004 | 01-May-2002 02824547.4 |
01-Jul-2009 ZL02824547.4 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
46077 |
China DIV |
19-Oct-2001 60/330,118 |
27-Apr-2009 | 01-May-2002 200910137707.6 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
27532 |
Singapore NP |
19-Oct-2001 60/330,118 |
16-Apr-2004 | 01-May-2002 200402237-2 |
31-May-2006 103725 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
27533 |
Canada NP |
19-Oct-2001 60/330,118 |
16-Apr-2004 | 01-May-2002 2,463,816 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | ||||||||||
27534 |
Mexico NP |
19-Oct-2001 60/330,118 |
19-Apr-2004 | 01-May-2002 PA/a/2004/003514 |
12-Nov-2010 280956 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
27535 |
Australia NP |
19-Oct-2001 60/330,118 |
20-Apr-2004 | 01-May-2002 2002307793 |
17-May-2007 2002307793 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal | |||||||||
27536 |
New Zealand NP |
19-Oct-2001 60/330,118 |
16-Apr-2004 | 01-May-2002 532348 |
12-Oct-2006 532348 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal |
53
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
27537 |
South Africa NP |
19-Oct-2001 60/330,118 |
08-Apr-2004 | 01-May-2002 2004/2756 |
31-May-2006 2004/02756 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal |
USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN CARDIOVASCULAR, CANCER AND WOUND HEALING | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | ||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
01/22752 |
PCT | 17-Nov-2000 60/248,582 |
15-Nov-2001 IL01/01059 |
Publ. Date: 23-May-2002 Publ. #: WO02/40629 |
Expired | HARATS Dror | ||||||||||
26025 |
Europe NP |
17-Nov-2000 60/248,582 |
15-May-2003 | 15-Nov-2001 01996590.4 |
20-Jan-2010 1443970 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
29027 |
Hong Kong NP |
17-Nov-2000 60/248,582 |
12-Jan-2005 | 15-Nov-2001 05100240.3 |
20-Aug-2010 HK1068057 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
47088 |
Europe DIV |
17-Nov-2000 60/248,582 |
04-Nov-2009 | 15-Nov-2001 09174998.6 |
Pending | HARATS Dror; BLOOM Nira | ||||||||||
49806 |
Europe DIV |
17-Nov-2000 60/248,582 |
01-Oct-2010 | 15-Nov-2001 EP10185193.9 |
Pending | HARATS Dror; BLOOM Nira |
54
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
49498 |
Hong Kong DIV |
17-Nov-2000 60/248,582 |
13-Oct-2010 | 15-Nov-2001 10109698.4 |
Pending | HARATS Dror; BLOOM Nira | ||||||||||
52630 |
Hong Kong DIV |
17-Nov-2000 60/248,582 |
2-Dec-2011 | 15-Nov-2001 11113094.5 |
3182.034HK21 | Pending | HARATS Dror; BLOOM Nira | |||||||||
26026 |
Israel NP |
17-Nov-2000 60/248,582 |
15-May-2003 | 15-Nov-2001 155940 |
30-Mar-2009 155940 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
26027 |
India NP |
17-Nov-2000 60/248,582 |
14-May-2003 | 15-Nov-2001 743/CHENP/2003 |
20-Nov-2007 211599 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
26028 |
USA NP |
17-Nov-2000 60/248,582 |
16-May-2003 | 15-Nov-2001 10/416,917 |
Abandoned | HARATS Dror | ||||||||||
26029 |
Canada NP |
17-Nov-2000 60/248,582 |
15-May-2003 | 15-Nov-2001 2,429,342 |
Pending | HARATS Dror; BLOOM Nira | ||||||||||
26030 |
Australia NP |
17-Nov-2000 60/248,582 |
15-May-2003 | 15-Nov-2001 2002224002 |
26-Jul-2007 2002224002 |
Abandoned | HARATS Dror | |||||||||
28653 |
Australia DIV |
17-Nov-2000 60/248,582 |
01-Dec-2004 | 15-Nov-2001 2003222427 |
09-Sep-2010 2003222427 |
Granted | HARATS Dror; BREITBART Eyal; BLOOM Nira | |||||||||
49098 |
Australia DIV |
15-Nov-2001 2002224002 |
25-Jun-2010 | 15-Nov-2001 2010202660 |
1-Dec 2011 2010202660 |
Granted | HARATS Dror; BREITBART Eyal; BLOOM Nira | |||||||||
26031 |
Japan NP |
17-Nov-2000 60/248,582 |
16-May-2003 | 15-Nov-2001 2002-543626 |
16-Jan-2009 4,243,653 |
Granted | HARATS Dror; BLOOM Nira |
55
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
26032 |
China NP |
17-Nov-2000 60/248,582 |
16-Jul-2003 | 15-Nov-2001 01822075.4 |
04-Feb-2009 ZL0182275.4 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
26033 |
Republic of Korea NP |
17-Nov-2000 60/248,582 |
17-May-2003 | 15-Nov-2001 2003-7006728 |
14-Nov-2008 869814 |
Granted | HARATS Dror | |||||||||
44105 |
Republic of Korea DIV |
17-Nov-2000 60/248,582 |
28-Jul-2008 | 15-Nov-2001 2008-7018598 |
10-Sep-2009 917854 |
Granted | HARATS Dror; BLOOM Nira | |||||||||
26034 |
Mexico NP |
17-Nov-2000 60/248,582 |
16-May-2003 | 15-Nov-2001 PA/a/2003/004325 |
15-Aug-2008 259670 |
Granted | HARATS Dror |
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
28918 |
USA CIP |
04-Oct-1998 126447 |
17-Nov-2004 10/989,724 |
Abandoned | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva | |||||||||||
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
30236 |
PCT | 17-Nov-2004 10/989,724 |
25-Sep-2005 IL2005/001022 |
Publ. Date: 26-May-2006 Publ. #: |WO2006/054281 |
Expired | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva | ||||||||||
39233 |
Europe NP |
17-Nov-2004 10/989,724 |
13-Jun-2007 | 25-Sep-2005 05788473.6 |
Abandoned | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
56
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
42004 |
Hong Kong NP |
17-Nov-2004 10/989,724 |
12-Sep-2007 07109873.6 |
Abandoned | HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva |
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
28376 |
USA CIP |
17-Nov-2000 60/248,582 |
14-Nov-2004 10/988,487 |
6-Dec 2011 8,071,740 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
50225 |
USA DIV |
17-Nov-2000 60/248,582 |
01-Feb-2011 | 14-Nov-2004 13/018,447 |
26-June 2012 8,206,743 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | |||||||||
50927 |
USA DIV |
17-Nov-2000 60/248,582 |
02-May-2011 | 14-Nov-2004 13/098,512 |
Aban | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
47407 |
USA DIV |
17-Nov-2000 60/248,582 |
13-Nov-2009 | 14-Nov-2004 12/591,252 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
60001 |
USA Con |
17-Nov-2000 60/248,582 |
13-July 2012 | 14-Nov-2004 13/549,355 |
3182.0370004 | Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael |
57
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
30269 |
PCT | 14-Nov-2004 10/988,487 |
14-Nov-2005 IL2005/001195 |
Publ. Date: 18-May-2006 Publ. #: WO2006/051545 |
Expired | HARATS Dror; GREENBERGER Shoshana | ||||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
47087 |
Europe DIV |
14-Nov-2004 10/988,487 |
28-Aug-2009 | 14-Nov-2005 09168899.4 |
2 Nov 2011 2174668 |
Grnated | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | |||||||||
49224 |
Hong Kong DIV |
12-Oct-2010 | 14-Nov-2005 10109638.7 |
15 June 2012 HK1143078 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
49804 |
Europe DIV |
14-Nov-2004 10/988,487 |
01-Oct-2010 | 14-Nov-2005 EP10185195.4 |
26 Sep 2012 2301586 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | |||||||||
49805 |
Europe DIV |
14-Nov-2004 10/988,487 |
30-Sep-2010 | 14-Nov-2005 EP10184033.8 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
39318 |
Australia NP |
14-Nov-2004 10/988,487 |
08-Jun-2007 | 14-Nov-2005 2005303385 |
Allowed | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael |
58
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
51825 |
Australia DIV |
14-Nov-2004 10/988,487 |
14-Nov-2005 | 28 June 2012 2011205076 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
53691 |
Australia DIV |
14-Nov-2004 10/988,487 |
15 June 2012 | 14-Nov-2005 2012203578 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
39323 |
New Zealand NP |
14-Nov-2004 10/988,487 |
05-Jun-2007 | 14-Nov-2005 555612 |
08-Apr-2010 555612 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | |||||||||
47297 |
New Zealand DIV |
14-Nov-2004 10/988,487 |
09-Oct-2009 | 14-Nov-2005 580289 |
05-Apr-2011 580289 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | |||||||||
39324 |
South Africa NP |
14-Nov-2004 10/988,487 |
05-Jun-2007 | 14-Nov-2005 2007/04687 |
31-Dec-2008 2007/04687 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat | |||||||||
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
[***] | ||||||||||
50629 |
Singapore DIV |
14-Nov-2004 10/988,487 |
11-Apr-2011 | 14-Nov-2005 201102612-7 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat | ||||||||||
39315 |
Israel NP |
14-Nov-2004 10/988,487 |
14-May-2007 | 14-Nov-2005 183187 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael |
59
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
50104 |
Israel DIV |
14-Nov-2004 10/988,487 |
31-Oct-2010 | 14-Nov-2005 209034 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat | ||||||||||
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
[***] | ||||||||||
39317 |
Canada NP |
14-Nov-2004 10/988,487 |
17-May-2007 | 14-Nov-2005 2,587,469 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
39319 |
Japan NP |
14-Nov-2004 10/988,487 |
14-May-2007 | 14-Nov-2005 2007-540833 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
52137 |
Japan Div |
14-Nov-2004 10/988,487 |
Sep 2011 | 14-Nov-2005 2011-191492 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
39320 |
China NP |
14-Nov-2004 10/988,487 |
13-Aug-2007 | 14-Nov-2005 200580046412.8 |
Aban | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael | ||||||||||
39321 |
Republic of Korea NP |
14-Nov-2004 10/988,487 |
14-Jun-2007 | 14-Nov-2005 2007-7013464 |
Pending | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael |
60
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
39322 |
Mexico NP |
14-Nov-2004 10/988,487 |
11-May-2007 | 14-Nov-2005 MX/a/2007/005783 |
8 May 2012 299008 |
Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat | |||||||||
52598 |
Mexico Div |
14-Nov-2004 10/988,487 |
14-Nov-2005 | 4 Sep 2012 303042 |
3182.037MX11 | Granted | HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat | |||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | [***] |
Method for treating vascular inflammation and psoriasis | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] | [***] | [***] | [***] | [***] | [***] |
61
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Treatment Of Inflammation | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] | ||||||||||
53305 |
PCT | 12 Dec 2011 61/569,545 and 12 Dec 2011 61/569,481 |
11 Dec 2012 PCT/US2012/068995 |
3182.014PC01 | Pending | MENDEL, Itzhak; FEIGE, Erez; YACOV, Niva; PROPHETE-MEIRAN, Oshrat; BREITBART, Eyal; SALEM, Yaniv |
62
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Treatment Methods Using Adenovirus | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
[***] |
[***] | [***] | [***] | [***] | [***] | [***] |
TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS | ||||||||||||||||
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
N/A |
USA CIP | 03-Mar-1994 08/254,015 |
28-Feb-1995 08395742 |
05-May-1998 5747340 |
Originally assinged to Syntex USA. Licensed to VBL | Granted | HARATS Dror; KURIHARA Hiroki; NANETTE BELLONI Paula; SIGAL Charles Elliott |
METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS |
63
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Our Ref |
Country |
Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
SKGF Ref |
Status |
Inventor | ||||||||
N/A |
PCT | 08-Dec-2009 61/283,696 |
07-Dec-2010 US2010/059204 |
Publ. Date: 16-Jun-2011 Publ. #: WO/2011/071859 |
As of June 2012, the applicant is also VBL | Pending | KOLESNICK, Richard, N. STANCEVIC, Branka; SADELAIN, Michel; FUKS, Zvi; VARDA-BLOOM, Nira; HARATS, Dror; | |||||||||
Trademark: VBL therapeutics & logo | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
47638 |
Europe | 5, 42 & 44 | 03-Dec-2009 008730541 |
02-Jun-2010 008730541 |
Registered | |||||||||||
Trademark: VASCULAR BIOGENICS | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
42092 |
Israel | 42 | 23-Aug-2007 203346 |
06-May-2009 203346 |
Registered | |||||||||||
43074 |
USA (Paris) |
42 | 23-Aug-2007 203346 |
14-Feb-2008 77/397,305 |
22-Jun-2010 3,805,239 |
Registered |
64
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
43075 |
Europe (Paris) |
5, 42 & 44 | 23-Aug-2007 203346 |
18-Feb-2008 006675599 |
20-Feb-2009 006675599 |
Registered | ||||||||||
Trademark: VBL VASCULAR BIOGENICS LTD. & Device | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
42199 |
Israel | 42 | 09-Sep-2007 203748 |
10-May-2009 203748 |
Registered | |||||||||||
43602 |
USA (Paris) |
42 | 09-Sep-2007 203748 |
03-Mar-2008 77/411,204 |
22-Jun-2010 3,805,245 |
Registered | ||||||||||
43603 |
Europe (Paris) |
42 | 09-Sep-2007 203748 |
04-Mar-2008 006721823 |
04-Sep-2009 006721823 |
Registered | ||||||||||
Trademark: VTS | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
42198 |
Israel | 5 | 09-Sep-2007 203747 |
06-May-2009 203747 |
Registered | |||||||||||
43600 |
USA (Paris) |
5 | 09-Sep-2007 203747 |
03-Mar-2008 77/411,151 |
20-Oct-2009 3,697,519 |
Registered |
65
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
43601 |
Europe (Paris) |
5 | 09-Sep-2007 203747 |
04-Mar-2008 006721484 |
20-Feb-2009 006721484 |
Registered | ||||||||||
Trademark: VASCULAR TARGETING SYSTEM VTS | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
41864 |
Israel | 5 | 23-Aug-2007 203345 |
08-Sep-2009 203345 |
Registered | |||||||||||
43072 |
USA (Paris) |
5 | 23-Aug-2007 203345 |
14-Feb-2008 77/397,328 |
18-May-2010 3,789,108 |
Registered | ||||||||||
43073 |
Europe (Paris) |
5, 42 & 44 | 23-Aug-2007 203345 |
18-Feb-2008 006675896 |
29-Jan-2009 006675896 |
Registered |
66
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
Trademark: VBL |
||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
42093 |
Israel | 42 | 23-Aug-2007 203347 |
22-Jan-2009 203347 |
Registered | |||||||||||
43076 |
USA (Paris) |
42 | 23-Aug-2007 203347 |
14-Feb-2008 77/397,293 |
14-Jul-2009 3,653,176 |
Registered | ||||||||||
43077 |
Europe (Paris) |
5, 42 & 44 | 23-Aug-2007 203347 |
18-Feb-2008 006673263 |
22-Jan-2009 006673263 |
Registered | ||||||||||
Trademark: VBL therapeutics & logo | ||||||||||||||||
Our Ref Client Ref |
Country |
Class |
Earliest Priority |
Filing Date Application No. |
Registration Date Registration No. |
SKGF Ref |
Status |
|||||||||
47612 |
Israel | 42 | 30-Nov-2009 225329 |
07-Feb-2011 225329 |
Registered | |||||||||||
47639 |
USA (Paris) |
42 | 30-Nov-2009 225329 |
26-Apr-2010 85/023,397 |
24-May-2011 3,964,829 |
Registered |
Domains: VBL |
67
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |
xxxxxxxxxxxxxxxxx.xxx |
xxxxxxxxxxxxxxxxxxxx.xxx
xxx-xxxxxxxxxxxx.xxx
xxxxxxxxxxxxxxx.xxx
xxxxx.xxx
xxxxxxxxxxxxxxxxx.xxx
xxx.xx.xx
xxxxx.xxx
xxxxxxxx-xxxxxxxxx.xxx |
68
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. |